Hyundai Pharm Co., Ltd.

Digmbio. Inc.

Changmin Park

Eunhee Kim

Jaekeol Rhee

Jeongun Hwang

Tae-Sung Koo

Younghoon Kim

Soonyoung Moon

Soyoun Kim

Doohyeok Pyeon

Juhee Lee

Jaehee Seol

Myounghyeon Shin

Ahram Shim

Sehwan Oh

Heeil Chae

Inhee Lee

Younggwan Kim

Sehoan Kim

Ki-Hong Jang

The present invention relates to isoquinolinone derivatives, a method for preparing the same, and a pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1 (PARP-1)-related diseases containing the same as an active ingredient. The isoquinolinone derivatives exhibit an excellent PARP-1 inhibitory effect at a concentration of nanomolar units, and further exhibit an excellent cytoprotective effect (apoptosis inhibitory effect) on ophthalmic diseases or disorders, specifically retinal disorders, and thus can be effectively used as a pharmaceutical composition for preventing or treating PARP-1-related diseases, for example, ophthalmic diseases or disorders, which contains the same as an active ingredient.

Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-&#x3b2;-hydroxy steroid dehydrogenase type 1 (11&#x3b2;-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-&#x3b2;-hydroxy steroid dehydrogenase type 1 (11&#x3b2;-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.

Compound for inhibiting 11&#x3b2;-hydroxy steroid dehydrogenase 1, and a pharmaceutical composition comprising the same

Growing community of inventors

Gyeonggi-do, South Korea

Changmin Park